LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth
Our findings establish that circulating LGALS3BP is a potential biomarker for liquid biopsy and uncover this protein as a suitable target for therapeutic strategies combining 1959-sss/DM4 ADC with an anti-PD-1 ICI for the treatment of LGALS3BP expressing neuroblastoma.
Authors
- Paola Lanuti (ORCID: https://orcid.org/0000-0003-4197-9780)
- Emily Capone (ORCID: https://orcid.org/0000-0001-6719-2535)
- Anna Piro (ORCID: https://orcid.org/0009-0000-8076-2491)
- Antonia Pece
- Vincenzo De Laurenzi (ORCID: https://orcid.org/0000-0002-7506-1743)
- Ilaria Cela (ORCID: https://orcid.org/0000-0003-3122-2688)
- Martina Colasante (ORCID: https://orcid.org/0000-0002-4993-9882)
- Pasquale Simeone (ORCID: https://orcid.org/0000-0003-4430-480X)
- Gianluca Sala (ORCID: https://orcid.org/0000-0002-4494-915X)
- Stefano Iacobelli
- Alessia Lamolinara (ORCID: https://orcid.org/0000-0002-7421-4509)
- Manuela Iezzi (ORCID: https://orcid.org/0000-0002-6296-6498)
- Rodolfo Ippoliti (ORCID: https://orcid.org/0000-0003-0652-3470)
- Giulio Lovato
Institutions
- University of L'Aquila (IT)
- University of Chieti-Pescara (IT)
- CTI BioPharma (Italy) (IT)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1186/s12967-025-06434-1
- Citations
- 7
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 9.72
Funders
- Associazione Italiana per la Ricerca sul Cancro